MAP3K9 and prostate carcinoma: Following the idea of targeting MLK1 as a therapeutic agent in treating prostate cancers, an earlier study in rats using a potent inhibitor of the MLK family showed that inhibiting MLKs did not affect either the survival or proliferation status of normal prostate epithelium in response to modulation of AR functions [31].